Abstract
Objectives A ‘Public Health Emergency of International Concern (PHEIC)’ monkeypox outbreak was declared by the World Health Organization on June 23, 2022. More than 16,000 monkeypox cases were reported in more than 75 countries across six regions as July 25.
Design A modeling study.
Setting and Participants Daily confirmed Monkeypox cases of the global, United States, Spain, Brazil, and United Kingdom were retrieved from the Global health team till September 23,2022. All conducted analyses are at the aggregate level.
without involvement of confidential information.
Primary and secondary outcome measures The Bayesian SIR (Susceptible-Infected-Recovered) model with Directed Acyclic Graphic method was used to estimate the basic/effective reproductive number (R0/ Re) and to assess the epidemic spread of Monkeypox in the globe.
Results The maximum estimated R0/ Re was 1.16 (1.15-1.17), 1.20 (1.20-1.20), 1.34 (1.34-1.35), and 1.33 (1.33-1.33) in United States, Spain, Brazil, and United Kingdom, respectively. The values of R0/ Re was toward to below 1 after August, 2022. The estimated infectious time before isolation ranged from 2.05 to 2.74 days.
Conclusions The PHEIC of global spreading of human Monkeypox outside Africa has been contained so as to avoid a pandemic in the light of the reasoning-based epidemic model assessment.
Strengths and limitations of this study
We estimated the epidemiology parameters based on the Bayesian SIR model for the uncertainty transmission of monkeypox under assumptions of homogeneous random mixing population and surveillance systems were the same across countries.
This approach can minimize biases between population, different surveillance systems across countries. Estimating results of R0 were limited but consistent between countries and similar to the simulation data by the deterministic SIR model.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The financial support from the Ministry of Science and Technology, Taiwan (MOST 111-2321-B-002-017).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The data on the Monkeypox outbreaks was retrieved from the Global health team for estimating of R0/Re (https://www.monkeypox.global.health/). The data of the global, United States, Spain, Brazil, and United Kingdom retrieved till September 23,2022.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data on the Monkeypox outbreaks was retrieved from the Global health team for estimating of R0/Re. The data of the global, United States, Spain, Brazil, and United Kingdom retrieved till September 23,2022.
https://www.monkeypox.global.health/
https://www.cdc.gov/poxvirus/monkeypox/response/2022/us-map.html.
